progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
Published 1 year ago • 62 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
1:44
extended interval dosing for pembrolizumab - lung cancer onctalk 2022
-
2:18
treatment of stage iv nsclc with high pd-l1 and atypical mutation - lung cancer onctalk 2022
-
1:57
keynote 091: adjuvant pembrolizumab - onctalk lung 2023
-
2:00
keynote 671: perioperative pembrolizumab for nsclc - onctalk lung 2023
-
4:56
dual immune checkpoint blockade with or without chemotherapy - lung cancer onctalk 2022
-
1:59:57
grace - global resource for advancing cancer education live stream
-
7:43
lung cancer video library - das - treatments - low or negative pdl1 and advanced non-squamous nsclc
-
6:56
gracecast - leading treatment options for patients with negative tumor pd-l1 nsclc with dr. stephen
-
1:48
preoperative or postoperative immunotherapy? - lung cancer onctalk 2022
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
4:12
trials for patients with actionable mutations, & the importance of quality of life - onctalk 2022
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
20:05
what is the role of immunotherapy for patients with advanced nsclc and a driver mutation?
-
2:35:24
onctalk 2020, connecting patients to the experts
-
3:01
immune checkpoints and pd-l1 - lcvl 2024
-
0:31
lobar versus sublobar resection in nsclc - onctalk lung 2023 - #shorts #youtubeshorts
-
5:21
polarix trial and polatuzumab in frontline chemotherapy for dlbcl - 2024 blood cancer onctalk